Print
New FDA approval of PARP inhibitor for maintenance therapy in ovarian cancer
https://www.facingourrisk.org/XRAY/fda-approval-niraparib-maintenance
Full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
The FDA has approved the use of niraparib (Zejula) as a maintenance therapy for women with advanced ovarian cancer who have had a complete or partial response to chemotherapy. (5/7/20)
Questions To Ask Your Health Care Provider
- Is maintenance therapy with Zejula an option for my ovarian cancer?
- If Zejula is not an option for me right now, might it be an option in the future?
- What side effects might I experience with this treatment?
- If I have serious side effects, will I need to stop treatment?
- Are any other agents available to treat my cancer?
Open Clinical Trials
The following studies look at PARP inhibitors and similar agents for treating people with ovarian cancer.
The following studies look at treatment for people with advanced solid tumors.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.